Dual inhibition of classical protein kinase C-α and protein kinase C-β isoforms protects against experimental murine diabetic nephropathy

Diabetes

Volumn 62, Issue 4, 2013, Pages 1167-1174

  Menne, Jan ^a,b   Shushakova, Nelli ^a,b   Bartels, Janina ^a   Kiyan, Yulia ^a   Laudeley, Robert ^a   Haller, Hermann ^a   Park, Joon Keun ^a   Meier, Matthias ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Phenos GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CGP 41252; CREATININE; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C ALPHA INHIBITOR; PROTEIN KINASE C BETA INHIBITOR; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; KIDNEY HYPERTROPHY; KIDNEY MASS; MALE; MICROALBUMINURIA; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RENAL PROTECTION; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; ISOENZYMES; KIDNEY; MALE; MICE; MICE, KNOCKOUT; ORGAN SIZE; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; STAUROSPORINE;

EID: 84875431757     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0534     Document Type: Article

References (34)

1. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care 2005;28:164-176
2. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001;44:1957-1972
3. Lee T-S, Saltsman KA, Ohashi H, King GL. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci USA 1989;86:5141-5145
4. Craven PA, DeRubertis FR. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose. J Clin Invest 1989;83:1667-1675
5. Dempsey EC, Newton AC, Mochly-Rosen D, et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 2000;279:L429-L438
6. Gould CM, Newton AC. The life and death of protein kinase C. Curr Drug Targets 2008;9:614-625
7. Menne J, Park J-K, Boehne M, et al. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. Diabetes 2004;53:2101-2109
8. Menne J, Meier M, Park JK, et al. Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C alpha signaling in-vivo. Kidney Int 2006;70:1456-1462
9. Meier M, Park JK, Overheu D, et al. Deletion of protein kinase C-b isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocininduced diabetic mouse model. Diabetes 2007;56:346-354
10. Meier M, Menne J, Park J-K, Haller H. Nailing down PKC isoform specificity in diabetic nephropathy two's company, three's a crowd. Nephrol Dial Transplant 2007;22:2421-2425
11. Meier M, Menne J, Haller H. Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice. Diabetologia 2009; 52:765-775
12. Menne J, Meier M, Park JK, Haller H. Inhibition of protein kinase C in diabetic nephropathy-where do we stand? Nephrol Dial Transplant 2009; 24:2021-2023
13. Meier M, Menne J, Park JK, et al. Deletion of protein kinase C-epsilon signaling pathway induces glomerulosclerosis and tubulointerstitial fibrosis in vivo. J Am Soc Nephrol 2007;18:1190-1198
14. Ohshiro Y, Ma RC, Yasuda Y, et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes 2006;55:3112-3120
15. Seo MS, Kwak N, Ozaki H, et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 1999;154:1743-1753
16. Meier M, Menne J, Park J-K, et al. Deletion of protein kinase C-{varepsilon} signaling pathway induces glomerulosclerosis and tubulointerstitial fibrosis in vivo. J Am Soc Nephrol 2007;18:1190-1198
17. Tossidou I, Teng B, Menne J, et al. Podocytic PKC-alpha is regulated in murine and human diabetes and mediates nephrin endocytosis. PLoS ONE 2010;5:e10185
18. Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008;57:460-469
19. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707-716
20. Shen GX. Selective protein kinase C inhibitors and their applications. Curr Drug Targets Cardiovasc Haematol Disord 2003;3:301-307
21. Swannie HC, Kaye SB. Protein kinase C inhibitors. Curr Oncol Rep 2002;4: 37-46
22. Way KJ, Chou E, King GL. Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol Sci 2000;21: 181-187
23. Teicher BA. Protein kinase C as a therapeutic target. Clin Cancer Res 2006; 12:5336-5345
24. Jirousek MR, Gillig JR, Gonzalez CM, et al. (S)-13-[(dimethylamino) methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k] pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem 1996;39:2664-2671
25. Ruboxistaurin: LY 333531. Drugs R D 2007;8:193-199
26. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992;89:11059-11063
27. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272: 728-731
28. Koya D, Jirousek MR, Lin Y-W, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997;100:115-126
29. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000;14: 439-447
30. Kelly DJ, Zhang Y, Hepper C, et al. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003;52:512-518
31. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005;28: 2686-2690
32. Tuttle KR, McGill JB, Haney DJ, Lin TE, Anderson PW. for the PKC-DRS P-D, and PKC-DRS 2 Study Groups. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2007;2: 631-636
33. Campochiaro PA. C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 2004;45:922-931
34. Tang S, Xiao V, Wei L, Whiteside CI, Kotra LP. Protein kinase C isozymes and their selectivity towards ruboxistaurin. Proteins 2008;72:447-460